Reformulation To think this has nothing to do with money (nuance) or trial design (Stauffer). FDA wants more info on new drug which is typical before they start the trial and why its more safer than the last one. Mostly retail in this stock which is good for me because i bought a shwack load at .17 and .20. People just assumed they didn't have the money lol.